Open access · OA
via OpenAlex
A Stage-Dependent Model of Mitochondrial Dysfunction in Alzheimer’s Disease: From Early Bioenergetic Vulnerability to Pathological Amplification
Oxford Journal of Student Scholarship · 2026
Loss of proteostasis
Mitochondrial dysfunction
Stem-cell exhaustion
Cell culture / in vitro
Human
Review
Abstract
Mitochondrial dysfunction(definition) is widely implicated in Alzheimer's disease, but its temporal and mechanistic relationship to classic AD pathology such as amyloid-beta and tau pathology remains largely unresolved.Some studies suggest that mitochondrial abnormalities occur before substantial plaque and neurofibrillary tangle (NFT) accumulation while others describe mitochondrial dysfunction as a downstream consequence.This review proposes a stage-dependent framework that reconciles these findings without treating mitochondrial dysfunction exclusively as a cause or consequence in Alzheimer's disease.The first stage is characterized by the appearance of early bioenergetic vulnerabilities and declining mitochondrial biogenesis before substantial Aβ plaque deposition.In the second stage, accumulating Aβ and tau then promote mitochondrial decompensation through mechanisms such as impaired OXPHOS, disrupted mitochondrial dynamics, and defective mitophagic clearance.Finally, in the third stage, persistent mitochondrial stress contributes to further tau hyperphosphorylation and disrupted tau proteostasis(definition), thereby reinforcing a cycle of MD and worsening AD pathology.This framework suggests therapeutic targets across stages of disease progression from preserving mitochondrial resilience to ensuring tau clearance.However, the proposed stages are largely overlapping rather than concrete chronological phases.Much of the supporting evidence derives from transgenic animal models, cultured cells, postmortem tissue analysis, and human induced pluripotent stem cell-derived neurons, limiting causal conclusions.Longitudinal studies in sporadic AD and the development of disease-specific mitochondrial biomarkers are needed to validate the model.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.65161/recapzwop5pd2luyb
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Wei, I. (2026). A Stage-Dependent Model of Mitochondrial Dysfunction in Alzheimer’s Disease: From Early Bioenergetic Vulnerability to Pathological Amplification. <em>Oxford Journal of Student Scholarship</em>. https://doi.org/10.65161/recapzwop5pd2luyb
Vancouver
Wei I. A Stage-Dependent Model of Mitochondrial Dysfunction in Alzheimer’s Disease: From Early Bioenergetic Vulnerability to Pathological Amplification. Oxford Journal of Student Scholarship. 2026. doi:10.65161/recapzwop5pd2luyb.
BibTeX
@article{ivy2026AStage,
title = {A Stage-Dependent Model of Mitochondrial Dysfunction in Alzheimer’s Disease: From Early Bioenergetic Vulnerability to Pathological Amplification},
author = {Ivy Wei},
journal = {Oxford Journal of Student Scholarship},
year = {2026},
doi = {10.65161/recapzwop5pd2luyb},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Antioxidants 2023
Open access · CC-BY
Effects of Redox Homeostasis and Mitochondrial Damage on Alzheimer’s Disease
Veterinary sciences 2026
Open access · OA
Canine Cognitive Dysfunction and Alzheimer's Disease: Pathophysiological Relationships and the Impact of Glymphatic System Impairment on Neurodegeneration.
Frontiers in aging neuroscience 2025
Open access · OA
The aggregate proteome of <i>Caenorhabditis elegans</i> mitochondria implicates shared mechanisms of aging and Alzheimer's disease.
International Journal of Molecular Sciences 2020
Open access · CC-BY
The Interplay between Mitochondrial Morphology and Myomitokines in Aging Sarcopenia
Frontiers in aging neuroscience 2026
Citation only
Peroxisomes in Alzheimer's disease: emerging mechanistic insights and therapeutic opportunities.
Biomedicines 2021
Open access · CC-BY